Penobscot Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Penobscot Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-320	Closed	-$247K	–	323
2026 Q1	$247K	Hold	320	–	–	0.02%	290
2025 Q4	$247K	Buy	+320	New	+$217K	0.02%	288
2025 Q3	–	Sell	-670	Closed	-$352K	–	322
2025 Q2	$352K	Hold	670	–	–	0.03%	249
2025 Q1	$425K	Hold	670	–	–	0.04%	222
2024 Q4	$477K	Hold	670	–	–	0.04%	209
2024 Q3	$704K	Hold	670	–	–	0.06%	183
2024 Q2	$704K	Hold	670	–	–	0.07%	179
2024 Q1	$645K	Sell	670 -4	-0.6%	-$3.8K	0.07%	185
2023 Q4	$592K	Hold	674	–	–	0.07%	187
2023 Q3	$555K	Hold	674	–	–	0.08%	174
2023 Q2	$484K	Hold	674	–	–	0.08%	156
2023 Q1	$554K	Sell	674 -375	-36%	-$283K	0.1%	148
2022 Q4	$757K	Hold	1,049	–	–	0.13%	129
2022 Q3	$723K	Hold	1,049	–	–	0.13%	130
2022 Q2	$620K	Hold	1,049	–	–	0.11%	145
2022 Q1	$733K	Hold	1,049	–	–	0.11%	147
2021 Q4	$662K	Buy	1,049 +124	+13%	+$76.2K	0.09%	153
2021 Q3	$560K	Hold	925	–	–	0.08%	157
2021 Q2	$517K	Buy	925 +250	+37%	+$127K	0.08%	158
2021 Q1	$319K	Hold	675	–	–	0.05%	192
2020 Q4	$326K	Hold	675	–	–	0.05%	180
2020 Q3	$378K	Sell	675 -125	-16%	-$75.8K	0.07%	155
2020 Q2	$499K	Hold	800	–	–	0.1%	138
2020 Q1	$391K	Hold	800	–	–	0.09%	141
2019 Q4	$300K	Hold	800	–	–	0.06%	171
2019 Q3	$222K	Hold	800	–	–	0.04%	188
2019 Q2	$250K	Hold	800	–	–	0.05%	179
2019 Q1	$328K	Hold	800	–	–	0.07%	160
2018 Q4	$299K	Buy	800 +100	+14%	+$36.6K	0.07%	156
2018 Q3	$283K	Hold	700	–	–	0.06%	176
2018 Q2	$241K	Hold	700	–	–	0.06%	187
2018 Q1	$241K	Hold	700	–	–	0.06%	188
2017 Q4	$263K	Hold	700	–	–	0.07%	169
2017 Q3	$313K	Hold	700	–	–	0.09%	153
2017 Q2	$344K	Hold	700	–	–	0.11%	146
2017 Q1	$271K	Hold	700	–	–	0.09%	155
2016 Q4	$257K	Hold	700	–	–	0.09%	157
2016 Q3	$281K	Hold	700	–	–	0.1%	153
2016 Q2	$244K	Hold	700	–	–	0.09%	162
2016 Q1	$252K	Hold	700	–	–	0.09%	161
2015 Q4	$380K	Hold	700	–	–	0.12%	143
2015 Q3	$326K	Hold	700	–	–	0.11%	150
2015 Q2	$357K	Hold	700	–	–	0.11%	157
2015 Q1	$316K	Hold	700	–	–	0.1%	157
2014 Q4	$287K	Hold	700	–	–	0.09%	157
2014 Q3	$252K	Buy	+700	New	+$235K	0.08%	161

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Penobscot Investment Management's REGN Position: Q2 2026 in Review

Penobscot Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 320 shares — an estimated $247K sold.

Penobscot Investment Management first reported a position in REGN in Q3 2014 and held it in 46 quarters. The position peaked at $757K in Q4 2022. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Penobscot Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Penobscot Investment Management sold 320 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $247K.
Penobscot Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2014 and held it in 46 quarters.
Penobscot Investment Management's Regeneron Pharmaceuticals position peaked at $757K in Q4 2022.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Penobscot Investment Management's 13F filing for Q2 2026, filed 24 Jul 2026.